Protein sequencing platform Quantum-Si's Q3 net loss widens

Quantum-Si

05/11/2025 21:56

Overview

Quantum-Si Q3 revenue was $552,000

Net loss widened to $35.7 mln from $25.3, reflecting increased operating expenses

Company achieved successful sequencing on prototype Proteus unit, development on track

Outlook

Quantum-Si plans to launch version 3 Library Prep Kit by year-end 2025

Company expects to deliver Proteus platform in second half of 2026

Quantum-Si using instrument acquisition options to counter NIH funding uncertainty

Result Drivers

VERSION 4 KIT LAUNCH - Launch of version 4 Sequencing Kit contributed to quarterly results

OPERATING EXPENSES - Rose to $40 mln from $28.5 mln a year ago, pressuring earnings

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$552,000
Q3 EPS
-$0.17
Q3 Net Income
-$35.70 mln
Q3 Operating Expenses
$39.97 mln
Q3 Operating Income
-$39.77 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Quantum-Si Inc is $3.00, about 38.7% above its November 4 closing price of $1.84

Press Release: ID:nBwbC1ctVa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)